Teleanu Maria-Veronica, Schneider Annika, Ball Claudia R, Leber Mathias Felix, Stange Christoph, Krieghoff-Henning Eva, Beck Katja, Heilig Christoph E, Kreutzfeldt Simon, Kuster Bernhard, Lipka Daniel B, Fröhling Stefan
Division of Translational Medical Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
National Center for Tumor Diseases (NCT), NCT Heidelberg, a Partnership Between DKFZ and Heidelberg University Hospital, 69120 Heidelberg, Germany.
Biomolecules. 2025 May 10;15(5):693. doi: 10.3390/biom15050693.
Precision oncology is becoming a mainstay in the standard of care for cancer patients. Recent technological advancements have significantly lowered the cost of various tumor profiling approaches, broadening the reach of molecular diagnostics and improving patient access to precision oncology. In parallel, drug development and discovery pipelines continue to evolve, driving targeted therapeutic options forward. Yet, not all patients harboring actionable molecular alterations respond to these interventions, and existing therapies do not cover the entire spectrum of potential molecular targets. In this review, we examine the current suite of omics technologies employed in clinical settings and underscore their roles in deepening our understanding of tumor biology and optimizing patient stratification for targeted treatments. We also highlight relevant precision oncology trials and share our own experiences using multi-omics data within a molecular tumor board framework. Finally, we discuss areas for future exploration aimed at propelling precision oncology to new heights.
精准肿瘤学正成为癌症患者标准治疗的中流砥柱。最近的技术进步显著降低了各种肿瘤分析方法的成本,扩大了分子诊断的范围,并改善了患者获得精准肿瘤学治疗的机会。与此同时,药物研发管道不断发展,推动了靶向治疗选择的进步。然而,并非所有具有可操作分子改变的患者都对这些干预措施有反应,而且现有疗法并未涵盖潜在分子靶点的全部范围。在这篇综述中,我们研究了目前在临床环境中使用的组学技术套件,并强调了它们在深化我们对肿瘤生物学的理解以及优化靶向治疗的患者分层方面的作用。我们还重点介绍了相关的精准肿瘤学试验,并分享了我们在分子肿瘤委员会框架内使用多组学数据的经验。最后,我们讨论了未来的探索领域,旨在将精准肿瘤学提升到新的高度。